Pakistan has a population of 194 million people, of which approximately 182 million live in malaria-endemic regions.
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although Plasmodium falciparum often takes the spotlight, given its more severe course. Chloroquine has long been the drug offered to patients with unconfi rmed malaria and those diagnosed with P vivax infection. Given the rise of drug resistance in many infectious agents due to poorly regulated drug use, it is no surprise that resistance has occurred in the organism that so frequently infects us. The time has come to recognise the threat of chloroquine-resistant P vivax in Pakistan, an entity that has been largely ignored.
Data on chloroquine resistance from Pakistan is scarce, even in the most recent global analysis.
3 Nevertheless, in 2013, the emergence of the F1076L mutant of the pvmdr1 gene-the mutation responsible for chloroquine resistance-in P vivax in Pakistan highlights the imminent threat of resistant Plasmodium. 4 In 2015, the fi rst case of resistance was identifi ed in a pregnant woman, and it was cured after switching to a combination of artemether and lumefantrine.
5
Implementation of the Roll Back Malaria initiative by Pakistan's Directorate of Malaria Control is the latest government attempt to eradicate malaria. It includes key elements of malaria control and prevention, but there is no mention of facilitating research on the Plasmodium gene polymorphisms in our population. We have reached an age of resistance, in which monotherapies and simple prevention are insuffi cient to combat the new generation of genetically diverse microorganisms armed with mutations that we have not prepared for. Our national malaria policy addresses chloroquine-resistant P falciparum, fi rst identifi ed 30 years ago, but has no mention of resistant P vivax or management guidelines for resistant P vivax infections. Given the bleak future in the presence of a malaria parasite that is resistant to the most common drug, relevant government-funded research is necessary to understand the burden of resistant malaria in Pakistan, and old guidelines have to be revised before an epidemic takes control.
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